Open AccessEVIDENCE-BASED TREATMENT OF REFRACTORY CHRONIC URTICARIA
Author(s) -
И В Данилычева
Publication year - 2014
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja535
Subject(s) - omalizumab , chronic urticaria , refractory (planetary science) , medicine , dermatology , intensive care medicine , disease , chronic disease , immunology , immunoglobulin e , biology , antibody , astrobiology
Despite advances in understanding of mechanisms of development of hives, many patients and their physicians remain unsatisfied results of treatment, lack of control of the disease. Now treatment of patients with the chronic urticarial has landmark character. The new indication for omalizumab was registered in Russia in 2014, giving the chance to achieve the control on a refractory form of urticaria. Omalizumab demonstrated rapid and beneficial effects on the signs and symptoms of chronic spontaneous urticaria torpid to H1blockers in the numerous studies.